Obexelimab

Summary

Obexelimab (CHEMBL4298134) is a phase-3 clinical-stage antibody; indicated across 3 conditions including autoimmune hemolytic anemia and systemic lupus erythematosus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298134
Name	Obexelimab
Type	Antibody
Max phase	3

Also known as: Obexelimab, XMAB-5871, Xmab5871, XMAB5871, OBEXELIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
autoimmune hemolytic anemia	3	MONDO:0020108	EFO:1001264
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05662241	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05786573	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
NCT06559163	PHASE2	RECRUITING	A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06564311	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT02725476	PHASE2	COMPLETED	Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
NCT02725515	PHASE2	COMPLETED	A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02867098	PHASE1	COMPLETED	XmAb5871 Bioavailability Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).